Form D · Biotechnology

Kytopen Corp.

Cambridge, MA · CIK 0001777277

Offering snapshot reported Feb 20, 2025 · SEC filing

Reported sold
$7.08M
Offering amount: $15M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 6, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 20, 2025Initial$7,082,651No comparison13SEC filing
Feb 15, 2024Initial$5,691,637No comparison22SEC filing
Oct 8, 2021Initial$32,479,963No comparison18SEC filing
Nov 6, 2020Initial$3,102,983No comparison11SEC filing
May 24, 2019Initial$4,350,000No comparison9SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-538793
Series AA Preferred Stock

Source: Form D, filed Feb 20, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Cullen Buie Director
Michael Chiu Director, Executive
Ann De Witt Director
Edward Freedman Director
Paulo Garcia Director, Executive, Promoter
Bethany Grant Executive
Paxton Major Director
Theresa Tribble Director
Julio Vega Executive
Adam Wieschhaus Director
Paul Wotton Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
750 Main Street
Cambridge, MA, 02139-4018